Premium
Management and treatment of the HCV‐infected kidney transplant patient
Author(s) -
Wong Tiffany,
Bloom Roy D.
Publication year - 2018
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/sdi.12766
Subject(s) - medicine , hepatitis c virus , adverse effect , intensive care medicine , population , kidney disease , kidney transplant , kidney transplantation , hepatitis c , disease , kidney , virus , immunology , environmental health
Abstract The prevalence of hepatitis C virus infection is increased in patients with end stage kidney disease compared to the general population and is an adverse outcome determinant. Direct‐acting antiviral therapy for hepatitis C virus is changing the management paradigm of infected kidney transplant candidates and recipients, with potential to reduce patient morbidity and mortality. This review describes the hepatic and nonhepatic manifestations of hepatitis C virus in kidney transplant patients as well as management and treatment strategies to optimize transplant outcomes, highlighting the importance of direct‐acting antivirals in this population.